| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 17 May 2024 | 9 May 2024 |
| To consider and approve the financial results for the period ended March 31, 2024 and other business matters Sotac Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024. (As Per NSE Announcement Dated on:17/05/2024) | ||
| Board Meeting | 5 Feb 2024 | 20 Jan 2024 |
| To consider and approve the financial results for the period ended December 31, 2023 and other business matters SOTAC PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 05-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Other business. Sotac Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 Sotac Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 05, 2024 for approval of financial results. (As Per NSE Announcement Dated on: 05/02/2024) | ||
| Board Meeting | 6 Nov 2023 | 30 Oct 2023 |
| Intimation of Board meeting for consideration of Unaudited Financial Results of the Company for the Half year ended on September 30, 2023 Sub: Outcome of Board Meeting held today i.e. on November 06, 2023 in terms of second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Ref: Sotac Pharmaceuticals Limited (SYMBOL/ISIN: SOTAC/INE0O2D01012)In reference to captioned subject, we hereby inform you that the Board of Directors of the Company, in their Board Meeting held today, i.e. on Monday, November 06, 2023, at the Registered Office of the Company situated at Plot No. PF-21, Nr. Acme Pharma, Opp. Teva Pharma Sanand GIDC-II, Sanand Ahmedabad-382110, which was commenced at 4:30 P.M. and concluded at 5:55 P.M., have;1. Considered, approved and taken on record the Unaudited Standalone and Consolidated financial result of the Company for the Half year ended on September 30, 2023, 2. Approved the Limited Review Report issued by Statutory Auditors of the Company for the Half year ended on September 30, 2023,3. Statement of Assets and Liabilities,4. Cash Flow Statement,5. Considered and approved all other business as per agenda circulated.Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the Standalone and Consolidated Unaudited Financial Results for the Half year ended September 30, 2023 and Limited Review Report issued by Statutory Auditors on the Standalone and Consolidated Unaudited Financial results for the half year ended on September 30, 2023. (As Per NSE Announcement Dated on: 06/11/2023) | ||
| Board Meeting | 11 Aug 2023 | 5 Aug 2023 |
| For consideration of Unaudited Financial Results for quarter ended on June 30, 2023 and to consider other business matters. SOTAC PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 11-Aug-2023 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2023 and Other business. Sotac Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 Sotac Pharmaceuticals Limited has informed the Exchange regarding Appointment of M/s. Suthar Haresh & Associates, Cost Accountants, and M/s. Keyur Shah & Co., Chartered Accountants . Sotac Pharmaceuticals Limited has informed the Exchange regarding Appointment of Ms Niyati Dipesh Parikh as Company Secretary & Compliance Officer of the company w.e.f. August 11, 2023. Sotac Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 11, 2023. Sotac Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended June 30, 2023. (As Per NSE Announcement Dated on 11/08/2023) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
